Literature DB >> 21813834

In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China.

Feng Lu1, Qi Gao, Kesinee Chotivanich, Hui Xia, Jun Cao, Rachanee Udomsangpetch, Liwang Cui, Jetsumon Sattabongkot.   

Abstract

In the face of recent increase of Plasmodium vivax malaria in central China, we conducted a study to evaluate in vitro susceptibility of temperate-zone P. vivax parasites to antimalarial drugs. During 2005-2006, in vitro drug susceptibility was measured for 42 clinical P. vivax isolates by using a schizont maturation inhibition technique. Geometric means of 50% inhibitory concentrations (IC(50)s) and 95% confidence intervals (CIs) were 10.87 (4.50-26.26) ng/mL for chloroquine, 4.21 (1.88-9.42-8) ng/mL for mefloquine, 11.82 (6.20-22.56) ng/mL for quinine, 0.13 (0.09-0.20) ng/mL for artesunate, 18.32 (8.08-41.50) ng/mL for pyrimethamine, and 17.73 (10.29-30.57) ng/mL for piperaquine. The IC(50) for chloroquine was lower than those obtained from isolates from Thailand and South Korea, suggesting that chloroquine remained effective against P. vivax malaria in central China. The results further indicated that temperate-zone P. vivax isolates from China were more susceptible to chloroquine, quinine, and mefloquine than isolates from Thailand.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813834      PMCID: PMC3144812          DOI: 10.4269/ajtmh.2011.10-0070

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  56 in total

1.  Gene amplification of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myanmar.

Authors:  Mallika Imwong; Sasithon Pukrittayakamee; Wirichada Pongtavornpinyo; Supatchara Nakeesathit; Shalini Nair; Paul Newton; Francois Nosten; Timothy J C Anderson; Arjen Dondorp; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

2.  Plasmodium vivax clinically resistant to chloroquine in Colombia.

Authors:  J Soto; J Toledo; P Gutierrez; M Luzz; N Llinas; N Cedeño; M Dunne; J Berman
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

3.  [Malaria situation in the People's Republic of China in 2006].

Authors:  Shui-Sen Zhou; Yi Wang; Lin-Hua Tang
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  2007-12

4.  Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam.

Authors:  Giao T Phan; Peter J de Vries; Binh Q Tran; Hung Q Le; Nam V Nguyen; Thang V Nguyen; Siem H Heisterkamp; Piet A Kager
Journal:  Trop Med Int Health       Date:  2002-10       Impact factor: 2.622

5.  Malaria mortality in Venezuela: focus on deaths due to Plasmodium vivax in children.

Authors:  Alfonso J Rodriguez-Morales; Jesús A Benítez; Melissa Arria
Journal:  J Trop Pediatr       Date:  2007-09-28       Impact factor: 1.165

6.  Determinants of in vitro drug susceptibility testing of Plasmodium vivax.

Authors:  B Russell; F Chalfein; B Prasetyorini; E Kenangalem; K Piera; R Suwanarusk; A Brockman; P Prayoga; P Sugiarto; Q Cheng; E Tjitra; N M Anstey; R N Price
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

Review 7.  Neglect of Plasmodium vivax malaria.

Authors:  J Kevin Baird
Journal:  Trends Parasitol       Date:  2007-10-22

8.  An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine.

Authors:  Oumaporn Tasanor; Harald Noedl; Kesara Na-Bangchang; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Acta Trop       Date:  2002-07       Impact factor: 3.112

9.  Plasmodium vivax trophozoites insensitive to chloroquine.

Authors:  Wesley W Sharrock; Rossarin Suwanarusk; Usa Lek-Uthai; Michael D Edstein; Varakorn Kosaisavee; Thomas Travers; Anchalee Jaidee; Kanlaya Sriprawat; Ric N Price; François Nosten; Bruce Russell
Journal:  Malar J       Date:  2008-05-27       Impact factor: 2.979

10.  Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase.

Authors:  Vivian N Hawkins; Alyson Auliff; Surendra Kumar Prajapati; Kanchana Rungsihirunrat; Hapuarachchige C Hapuarachchi; Amanda Maestre; Michael T O'Neil; Qin Cheng; Hema Joshi; Kesara Na-Bangchang; Carol Hopkins Sibley
Journal:  Malar J       Date:  2008-04-28       Impact factor: 2.979

View more
  13 in total

1.  In vitro susceptibility of Plasmodium vivax to antimalarials in Colombia.

Authors:  Diana Fernández; César Segura; Margarita Arboleda; Giovanny Garavito; Silvia Blair; Adriana Pabón
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

2.  Blood stage of Plasmodium vivax in central China is still susceptible to chloroquine plus primaquine combination therapy.

Authors:  Guoding Zhu; Feng Lu; Jun Cao; Huayun Zhou; Yaobao Liu; Eun-Taek Han; Qi Gao
Journal:  Am J Trop Med Hyg       Date:  2013-05-13       Impact factor: 2.345

3.  A case of congenital plasmodium vivax malaria from a temperate region in Central China.

Authors:  Xue Liu; Zhi-Yong Tao; Qiang Fang; Xue-Mei Wang; Hui Zhang; Jose A Stoute; Hui Xia; Liwang Cui
Journal:  Malar J       Date:  2012-06-06       Impact factor: 2.979

4.  Prevalence of drug resistance-associated gene mutations in Plasmodium vivax in Central China.

Authors:  Feng Lu; Bo Wang; Jun Cao; Jetsumon Sattabongkot; Huayun Zhou; Guoding Zhu; Kwonkee Kim; Qi Gao; Eun-Taek Han
Journal:  Korean J Parasitol       Date:  2012-11-26       Impact factor: 1.341

5.  The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.

Authors:  Michael Delves; David Plouffe; Christian Scheurer; Stephan Meister; Sergio Wittlin; Elizabeth A Winzeler; Robert E Sinden; Didier Leroy
Journal:  PLoS Med       Date:  2012-02-21       Impact factor: 11.069

6.  Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India.

Authors:  Sneh Shalini; Saumyadripta Chaudhuri; Patrick L Sutton; Neelima Mishra; Nalini Srivastava; Joseph K David; K John Ravindran; Jane M Carlton; Alex Eapen
Journal:  Malar J       Date:  2014-03-31       Impact factor: 2.979

7.  Return of chloroquine sensitivity to Africa? Surveillance of African Plasmodium falciparum chloroquine resistance through malaria imported to China.

Authors:  Feng Lu; Meihua Zhang; Richard L Culleton; Sui Xu; Jianxia Tang; Huayun Zhou; Guoding Zhu; Yaping Gu; Chao Zhang; Yaobao Liu; Weiming Wang; Yuanyuan Cao; Julin Li; Xinlong He; Jun Cao; Qi Gao
Journal:  Parasit Vectors       Date:  2017-07-26       Impact factor: 3.876

8.  Longitudinal in vitro surveillance of Plasmodium falciparum sensitivity to common anti-malarials in Thailand between 1994 and 2010.

Authors:  Daniel Parker; Rujira Lerdprom; Wanna Srisatjarak; Guiyun Yan; Jetsumon Sattabongkot; James Wood; Jeeraphat Sirichaisinthop; Liwang Cui
Journal:  Malar J       Date:  2012-08-21       Impact factor: 2.979

9.  Further evaluation of the NWF filter for the purification of Plasmodium vivax-infected erythrocytes.

Authors:  Jiangyan Li; Zhiyong Tao; Qian Li; Awtum Brashear; Ying Wang; Hui Xia; Qiang Fang; Liwang Cui
Journal:  Malar J       Date:  2017-05-17       Impact factor: 2.979

10.  Quantifying effect of geographic location on epidemiology of Plasmodium vivax malaria.

Authors:  Andrew A Lover; Richard J Coker
Journal:  Emerg Infect Dis       Date:  2013-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.